Alpha 2.0
Login Register
» Articles » PMID: 29795270

Next-generation Sequencing for Measuring Minimal Residual Disease in AML

Overview
Journal Nat Rev Clin Oncol
Specialty Oncology
Date 2018 May 26
PMID 29795270
Citations 3
Authors
Roland B Walter
Frederick R Appelbaum
Affiliations
Soon will be listed here.
Citing Articles

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.

Hashimoto M, Saito Y, Nakagawa R, Ogahara I, Takagi S, Takata S Nat Cancer. 2022; 2(3):340-356.

PMID: 35121960 DOI: 10.1038/s43018-021-00177-w.

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

Hanekamp D, Tettero J, Ossenkoppele G, Kelder A, Cloos J, Schuurhuis G Cancers (Basel). 2021; 13(11).

PMID: 34073205 PMC: 8198261. DOI: 10.3390/cancers13112597.

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Fuda F, Chen W Curr Hematol Malig Rep. 2018; 13(6):455-466.

PMID: 30446941 DOI: 10.1007/s11899-018-0479-1.